贝伐单抗维持治疗脑转移瘤疗效与安全性分析(3)
[4] Dvorak HF. Vascular permeability factor/vascular endothelial growth factor： a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy[J]. J Clin Oncol，2002，20(21)： 4368-4380.
[5] LS Kim，S Huang， W Lu，et al Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice[J].Clin Exp Metastasis，2004，21(2)：107-118.
[6]Jain RK， di Tomaso E， Duda DG et al. Angiogenesis in brain tumours[J].Nat Rev Neurosci，2007， 8(8)： 610-622.
, 百拇医药
[7]Ebbers HC， van Meer PJ， Moors EH， et al. Measures of biosimilarity in monoclonal antibodies in oncology： the case of bevacizumab[J].Drug Discov Today，2013，18(17-18)： 872-879.
[8]Besse B， Lasserre SF， Compton P， et al. Bevacizumab safety in patients with central nervous system metastases[J].Clin Cancer Res，2010， 16： 269-278.
[9]Lois A. Lampson.Monoclonal antibodies in neuro-oncology Getting past the blood-brain barrier[J].2011，3(2)：153-160.
, 百拇医药
[10] Y Yoshida，S Hoshino N Aisu，et al.Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer[J].Case Report in Oncology，2014，7(7)：117-121.
[11]Ferrara N， Gerber HP， LeCouter，et al.The biology of VEGF and its receptors[J].Nat Med，2003，9(6)：669-676.
[12] Ay I， Francis JW， Brown RH. et al.VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice[J].Brain Res，2008，1234(3)：198-205.
, http://www.100md.com
[13]Gordon MS， Margolin K， Talpaz M， et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J].J Clin Oncol，2001，19(3)： 843-850.
[14]Socinski MA， Langer CJ， Huang JE， et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases[J].J Clin Oncol， 2009，27(31)： 5255- 5261.
[15]Craig P， Carden， James M.G. Larkin， et al. What is the risk of intracranial bleeding during anti-VEGF therapy[J].Neuro-oncology，2008，10(4)：624-630.
, http://www.100md.com
[16]C Levy， D Allouache，J Lacroix，et al. REBECA： a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours[J].2014，25(12)：2351-2356.
[17]Ranpura V， Hapani S， Chuang J， et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients： a meta-analysis of randomized controlled trials[J].2010，49(3)： 287-297.
, http://www.100md.com
[18]Pei-Yuan Zuo.， Xing-Lin Chen， Yu-Wei Liu，et al. Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab： A Meta-Analysis[J].Plos One，2014，9(7)：e102484.
[19]Ignoffo RJ. Overview of bevacizumab： a new cancer therapeutic strategy targeting vascular endothelial growth factor[J].Am J Health Syst Pharm， 2004， 61(21 Suppl 5)： S21-26.
[20] Wang Y， Fei D， Vanderlaan M， et al. Biological activity of bevacizumab， a humanized anti-VEGF antibody in vitro[J].Angiogenesis， 2004， 7(4)： 335-345.
, 百拇医药
[21]Fujisawa T， Watanabe J， Akaboshi M， et al. Immunohistochemical study on VEGF expression in endometrial carcinoma--comparison with p53 expression， angiogenesis， and tumor histologic grade[J].J Cancer Res Clin Oncol， 2001， 127(11)： 668-674.
[22]Ebbers HC， van Meer PJ， Moors EH， et al. Measures of biosimilarity in monoclonal antibodies in oncology： the case of bevacizumab[J].Drug Discov Today， 2013，18(17-18)： 872-879.編辑/金昊天, 百拇医药(石大友 廖立潇 熊超)
[5] LS Kim，S Huang， W Lu，et al Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice[J].Clin Exp Metastasis，2004，21(2)：107-118.
[6]Jain RK， di Tomaso E， Duda DG et al. Angiogenesis in brain tumours[J].Nat Rev Neurosci，2007， 8(8)： 610-622.
, 百拇医药
[7]Ebbers HC， van Meer PJ， Moors EH， et al. Measures of biosimilarity in monoclonal antibodies in oncology： the case of bevacizumab[J].Drug Discov Today，2013，18(17-18)： 872-879.
[8]Besse B， Lasserre SF， Compton P， et al. Bevacizumab safety in patients with central nervous system metastases[J].Clin Cancer Res，2010， 16： 269-278.
[9]Lois A. Lampson.Monoclonal antibodies in neuro-oncology Getting past the blood-brain barrier[J].2011，3(2)：153-160.
, 百拇医药
[10] Y Yoshida，S Hoshino N Aisu，et al.Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer[J].Case Report in Oncology，2014，7(7)：117-121.
[11]Ferrara N， Gerber HP， LeCouter，et al.The biology of VEGF and its receptors[J].Nat Med，2003，9(6)：669-676.
[12] Ay I， Francis JW， Brown RH. et al.VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice[J].Brain Res，2008，1234(3)：198-205.
, http://www.100md.com
[13]Gordon MS， Margolin K， Talpaz M， et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J].J Clin Oncol，2001，19(3)： 843-850.
[14]Socinski MA， Langer CJ， Huang JE， et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases[J].J Clin Oncol， 2009，27(31)： 5255- 5261.
[15]Craig P， Carden， James M.G. Larkin， et al. What is the risk of intracranial bleeding during anti-VEGF therapy[J].Neuro-oncology，2008，10(4)：624-630.
, http://www.100md.com
[16]C Levy， D Allouache，J Lacroix，et al. REBECA： a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours[J].2014，25(12)：2351-2356.
[17]Ranpura V， Hapani S， Chuang J， et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients： a meta-analysis of randomized controlled trials[J].2010，49(3)： 287-297.
, http://www.100md.com
[18]Pei-Yuan Zuo.， Xing-Lin Chen， Yu-Wei Liu，et al. Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab： A Meta-Analysis[J].Plos One，2014，9(7)：e102484.
[19]Ignoffo RJ. Overview of bevacizumab： a new cancer therapeutic strategy targeting vascular endothelial growth factor[J].Am J Health Syst Pharm， 2004， 61(21 Suppl 5)： S21-26.
[20] Wang Y， Fei D， Vanderlaan M， et al. Biological activity of bevacizumab， a humanized anti-VEGF antibody in vitro[J].Angiogenesis， 2004， 7(4)： 335-345.
, 百拇医药
[21]Fujisawa T， Watanabe J， Akaboshi M， et al. Immunohistochemical study on VEGF expression in endometrial carcinoma--comparison with p53 expression， angiogenesis， and tumor histologic grade[J].J Cancer Res Clin Oncol， 2001， 127(11)： 668-674.
[22]Ebbers HC， van Meer PJ， Moors EH， et al. Measures of biosimilarity in monoclonal antibodies in oncology： the case of bevacizumab[J].Drug Discov Today， 2013，18(17-18)： 872-879.編辑/金昊天, 百拇医药(石大友 廖立潇 熊超)